Abstract
Inhibitors of estrogen-related pathways have been used with some success in the treatment of breast cancer. These include the antiestrogens tamoxifen, more recently faslodex, and the aromatase inhibitor anastrazole. However, failure and recurrence rates are substantial with drugs countering the effects of estrogens. Progestins, unlike estrogens, have generally been considered to oppose breast cancer and have been used with reasonable efficacy after antiestrogen failure. However, a building body of evidence, from cell culture, animal studies, and, most recently, several major clinical studies involving hormone replacement therapy, strongly supports the notion that progestins generally stimulate breast cancer. Our studies and those of others suggest that progestins increase the numbers of breast cancer cells by both stimulating the rate of proliferation and inhibiting cell death. These data indicate that progestin-related pathways might provide effective targets for breast cancer therapy. This review addresses the rationale for using inhibitors of progestin-related pathways to treat breast cancer and comments on some possible points of attack.
Keywords: estrogen, progestins, estrogens, aromatase
Current Cancer Drug Targets
Title: A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Volume: 4 Issue: 2
Author(s): Michael R. Moore
Affiliation:
Keywords: estrogen, progestins, estrogens, aromatase
Abstract: Inhibitors of estrogen-related pathways have been used with some success in the treatment of breast cancer. These include the antiestrogens tamoxifen, more recently faslodex, and the aromatase inhibitor anastrazole. However, failure and recurrence rates are substantial with drugs countering the effects of estrogens. Progestins, unlike estrogens, have generally been considered to oppose breast cancer and have been used with reasonable efficacy after antiestrogen failure. However, a building body of evidence, from cell culture, animal studies, and, most recently, several major clinical studies involving hormone replacement therapy, strongly supports the notion that progestins generally stimulate breast cancer. Our studies and those of others suggest that progestins increase the numbers of breast cancer cells by both stimulating the rate of proliferation and inhibiting cell death. These data indicate that progestin-related pathways might provide effective targets for breast cancer therapy. This review addresses the rationale for using inhibitors of progestin-related pathways to treat breast cancer and comments on some possible points of attack.
Export Options
About this article
Cite this article as:
Moore R. Michael, A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481515
DOI https://dx.doi.org/10.2174/1568009043481515 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Docking and In Silico ADMET Study Reveals Flavonoids as a Potential Inhibitor of Aromatase
Letters in Drug Design & Discovery Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Clinical Proteomics of Breast Cancer
Current Genomics From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry A Hidden Human Proteome Signature Characterizes the Epithelial Mesenchymal Transition Program
Current Pharmaceutical Design Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Acoustic Radiation Force Impulse (ARFI) Imaging: A Review
Current Medical Imaging Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Cannabinoids and Cancer
Mini-Reviews in Medicinal Chemistry MiR-22-3p Regulates Amyloid β Deposit in Mice Model of Alzheimer's Disease by Targeting Mitogen-activated Protein Kinase 14
Current Neurovascular Research microRNAs: Small Molecules with a Potentially Role in Oral Squamous Cell Carcinoma
Current Pharmaceutical Design Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry Flexible Estrogen Receptor Modulators: Synthesis, Biochemistry and Molecular Modeling Studies for 3-Benzyl-4,6-diarylhex-3-ene and 3,4,6-Triarylhex-3-ene Derivatives
Medicinal Chemistry